Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...

Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to ...

Keytruda’s first-line boost could come soon. Data from Keytruda’s first-line lung cancer study will be presented at the European Society of Medical Oncology meeting in October--the lung cancer study ...

GlobalData analyst Biswajit Podder notes that Sac-TMT-Keytruda could influence the NSCLC treatment paradigm on a regional level if approved.

The verdict is the latest twist in patent litigation between MSD and Halozyme, in which the latter is claiming that Keytruda ...

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo. Keytruda (pembrolizumab) in the ...

For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds A large clinical trial shows that for many patients with the most common type of lung cancer, ...